Hence, rat glioma 101.8 is potentially a quite reliable preclinical model to evaluate the anti-tumor efficacy of SOX2-, OLIG1/2-, and PDGFRA-targeting therapy approaches [25,32]. The gene discussed is OLIG1; the disease is central nervous system cancer.